MD Nexus
History and Physical Examination
Trametinib (Mekinist)
Indications
Metastatic Melanoma with BRAF V600E Gene Mutation
(see
Melanoma
, [[Melanoma]]): used in combination with the BRAF inhibitor Dabrafenib (Tafinlar) (see
Dabrafenib
, [[Dabrafenib]]), due to resistance to Dabrafenib which develops within 6-7 mo
FDA approved for this indication May 30, 2013
Pharmacology
MEK Inhibitor
Administration
xxx
Adverse Effects
Other Adverse Effects
xxxx
References
xxx